Press Releases for NKTR

Press Releases
AstraZeneca: Third Quarter and Nine Months Results 2009
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
West Announces Second Quarter 2009 Results ; - Adjusted Diluted EPS (1) of $0.58 -; - Revises Adjusted Diluted EPS(1) Estimate to Between $2.10 and $2.20 -; - Conference Call Scheduled for 9 A.M. Today -
Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
Cephalon Appoints Sarma P. Duddu As General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
Nektar Announces Retirement of Irwin Lerner from Board of Directors
First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Nektar Therapeutics to Webcast R&D Day on November 12th
Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference
Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
Nektar Therapeutics Announces Second Quarter 2008 Results
Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolytics
Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit - May 27 2008 1:01AM
Amikacin Inhale Shows Promising Results in Phase II Study - May 27 2008 12:57AM
Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings - May 27 2008 12:55AM
Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress - Jun 2 2008 12:04AM
Nektar Therapeutics Announces First Quarter 2008 Results - Jun 2 2008 12:04AM
Nektar Receives Patent Covering Pulmonary Targeted Antibiotics - Jun 2 2008 12:04AM
NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting - Jun 2 2008 12:04AM
Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
BellwetherReport.com Initiates Analyst Coverage on CPHD, STSA, CYTR and NKTR
Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
BellwetherReport.com Free Analyst Review for NKTR, MNKD, EPMD and AMGI
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients